The Trump administration is set to weigh in on whether the hallucinogenic compound psilocybin should be moved into a less restrictive class of drugs under federal regulations.

Regulation of psilocybin — the “magic” substance in psychedelic mushrooms — has been a hot-button issue for Californians in recent years, but repeated attempts by state lawmakers to allow medical use of the substance have floundered.

Now it seems change may come at the federal level.

The U.S. Department of Health and Human Services is weighing a petition sent earlier this month by the Drug Enforcement Administration to review the scientific evidence and consider easing restrictions.

Psilocybin is currently classified as a Schedule I narcotic, the most restrictive category under federal law, reserved for drugs “wi

See Full Page